Determination of HIV-1 subtypes in injecting drug users in Bangkok, Thailand, using peptide-binding enzyme immunoassay and heteroduplex mobility assay: evidence of increasing infection with HIV-1 subtype E. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Determination of HIV-1 subtypes in injecting drug users in Bangkok, Thailand, using peptide-binding enzyme immunoassay and heteroduplex mobility assay: evidence of increasing infection with HIV-1 subtype E.

AIDS. 1995 Aug;9(8):843-9. Unique Identifier : AIDSLINE MED/96014956
Wasi C; Herring B; Raktham S; Vanichseni S; Mastro TD; Young NL; Rubsamen-Waigmann H; von Briesen H; Kalish ML; Luo CC; et al; Department of Microbiology, Faculty of Medicine, Siriraj; Hospital, Mahidol University, Bangkok, Thailand.


Abstract: OBJECTIVES: To evaluate the sensitivity and specificity of peptide-binding enzyme immunoassay (PEIA) and heteroduplex mobility assay (HMA) for the determination of HIV-1 subtypes B and E; to determine the proportions of infections due to subtypes B and E over time; and to generate data on DNA sequences of the C2-V3 region of the env genes. METHODS: HIV-1 subtyping was conducted by PEIA and HMA on blood specimens obtained from 97 injecting drug users (IDU) infected with HIV between 1988 and 1993. Genetic sequencing was performed on 84 specimens. RESULTS: Both laboratory methods were highly sensitive and specific for the determination of HIV-1 subtypes B and E. The two tests were complementary; samples which could not be typed by HMA were correctly typed by PEIA and vice versa. While subtype B accounted for 80.4% (78 out of 97) of infections overall, the proportion of new infections due to subtype E increased from 2.6% (one out of 38) in 1988-1989 to 25.6% (11 out of 43) in 1990-1991, and to 43.8% (seven out of 16) in 1992-1993 (chi 2 for linear trend, P < 0.001). CONCLUSIONS: HMA and PEIA are practical, sensitive and specific laboratory methods for the determination of HIV-1 subtypes in Thailand, and may be useful in other geographic areas to define the molecular epidemiology of the global HIV-1 pandemic. Data suggest that the proportion subtype E infections have increased among Bangkok IDU from 1988 through 1993.
Keywords: Adult Amino Acid Sequence Epidemiology, Molecular Evaluation Studies Female Genes, env Human HIV Infections/*COMPLICATIONS/EPIDEMIOLOGY/*VIROLOGY HIV-1/*CLASSIFICATION/GENETICS/*ISOLATION & PURIF Immunoenzyme Techniques/STATISTICS & NUMER DATA Male Molecular Sequence Data Peptides/GENETICS Sensitivity and Specificity Substance Abuse, Intravenous/*COMPLICATIONS/*VIROLOGY Thailand/EPIDEMIOLOGY JOURNAL ARTICLEKWDadultaminoacidsequenceepidemiology,molecularevaluationstudiesfemalegenes,envhumanhivinfections/KWDcomplications/epidemiology/KWDvirologyhiv-1/KWDclassification/genetics/KWDisolation&purifimmunoenzymetechniques/statistics&numerdatamalemolecularsequencedatapeptides/geneticssensitivityandspecificitysubstanceabuse,intravenous/KWDcomplications/KWDvirologythailand/epidemiologyjournalarticle
960228
M9621073

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .